Experimental vaccine against cancer progression showed a broad protection against the virus that carries the risk of developing tumors. Innovative vaccine is the U.S. pharmaceutical company Merck & Co.
In its report, the vaccine makers explained that the survey results support the company's plan to submit a new vaccine approved in the U.S. by the end of the year. In the event that it is received, the new vaccine can be introduced next year.
Gardasil is the first vaccine company that was developed in 2006 It protects against several strains of the virus: 6, 11, 16 and 18, as the risk for cervical cancer are strains 16 and 18, and 6 and 11 cause the formation of genital warts. The company's new vaccine offers greater protection.
Company Merck & Co has already conducted clinical trials to test the safety and efficacy of the new vaccine, and the results should be presented at a special meeting of doctors in Florence, Italy this week, said the report.